http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013523178-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2521-101 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2011-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013523178-A |
| titleOfInvention | KRAS primers and probes |
| abstract | PCR primers and probes for detecting KRAS mutations in DNA, methods of using these PCR primers and probes to detect KRAS mutations, and cancer susceptibility to chemotherapy directed against epidermal growth factor receptor To provide a method for predicting The present invention provides oligonucleotide primers or probes for detection of mutations in the KRAS gene. The present invention also provides a method for detecting mutations in the KRAS gene using the oligonucleotide primers or probes disclosed herein. Furthermore, the present invention uses codon 12 in exon 2 of the KRAS gene in DNA using methods to obtain DNA from tumors and utilizing at least one of the oligonucleotide primers and / or probes of the present invention. And / or a method for predicting the susceptibility of a tumor in a patient to chemotherapy directed against epidermal growth factor receptor, comprising determining whether or not a codon 13 mutation is present. [Selection figure] None |
| priorityDate | 2010-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 174.